Short Interest in Equillium, Inc. (NASDAQ:EQ) Expands By 31.5%

Equillium, Inc. (NASDAQ:EQ) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 103,600 shares, a growth of 31.5% from the December 15th total of 78,800 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily volume of 187,700 shares, the short-interest ratio is currently 0.6 days.

Institutional Trading of Equillium

A hedge fund recently raised its stake in Equillium stock. Renaissance Technologies LLC grew its stake in Equillium, Inc. (NASDAQ:EQ) by 43.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 300,400 shares of the company’s stock after purchasing an additional 91,200 shares during the period. Renaissance Technologies LLC owned about 0.85% of Equillium worth $208,000 at the end of the most recent quarter. Institutional investors own 27.05% of the company’s stock.

Equillium Trading Down 8.0 %

Shares of EQ traded down $0.06 during midday trading on Friday, hitting $0.64. 120,797 shares of the company’s stock traded hands, compared to its average volume of 138,057. Equillium has a 1 year low of $0.56 and a 1 year high of $3.25. The firm’s fifty day moving average is $0.71 and its 200-day moving average is $0.82. The stock has a market capitalization of $22.81 million, a price-to-earnings ratio of -4.60 and a beta of 1.78.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.